SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories issues NCD worth Rs 500 crore

24 Nov 2012 Evaluate

Ranbaxy Laboratories has issued 5,000 secured 9.20% Redeemable Non-Convertible Debentures (NCD) of face value of Rs 10,00,000 each, for cash at par, aggregating Rs 500 crore, on a private placement basis, for general corporate purposes. These debentures have been rated AA+ by CARE and are proposed to be listed on stock National Exchange of India (NSE).

In another development, the company had recalled Atorvastatin from the USA market which will cause temporary disruption to the market of this product.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×